Literature DB >> 28096284

Pulmonary vascular and cardiac impairment in interstitial lung disease.

Marios Panagiotou1, Alistair C Church1, Martin K Johnson1, Andrew J Peacock1.   

Abstract

Pulmonary vascular and cardiac impairment is increasingly appreciated as a major adverse factor in the natural history of interstitial lung disease. This clinically orientated review focuses on the current concepts in the pathogenesis, pathophysiology and implications of the detrimental sequence of increased pulmonary vascular resistance, pre-capillary pulmonary hypertension and right heart failure in interstitial lung disease, and provides guidance on its management.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28096284     DOI: 10.1183/16000617.0053-2016

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  9 in total

1.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

2.  Developmental Origins of Chronic Lung Diseases. Mechanical Stretch, Micro-RNAs, and Hydrogels.

Authors:  Matthew D McGraw; Laura G Sherlock; Kolene L Bailey; Steven H Abman
Journal:  Am J Respir Cell Mol Biol       Date:  2018-08       Impact factor: 6.914

3.  Pulmonary Vascular and Right Ventricular Burden During Exercise in Interstitial Lung Disease.

Authors:  Rudolf K F Oliveira; Aaron B Waxman; Paul J Hoover; Paul F Dellaripa; David M Systrom
Journal:  Chest       Date:  2020-03-12       Impact factor: 9.410

Review 4.  Lung function and cardiovascular disease: A link.

Authors:  Sergio H R Ramalho; Amil M Shah
Journal:  Trends Cardiovasc Med       Date:  2020-01-03       Impact factor: 6.677

5.  Lower DLco% identifies exercise pulmonary hypertension in patients with parenchymal lung disease referred for dyspnea.

Authors:  Richard H Zou; William D Wallace; S Mehdi Nouraie; Stephen Y Chan; Michael G Risbano
Journal:  Pulm Circ       Date:  2020-02-19       Impact factor: 3.017

6.  Airway-centered Interstitial Fibrosis Involving Smooth Muscle Hyperplasia with Severe Pulmonary Hypertension.

Authors:  Kyoko Gocho; Tokuhiro Kimura; Nobuyuki Hamanaka; Toshiharu Ishii; Tamiko Takemura; Kunihiko Shimizu
Journal:  Intern Med       Date:  2020-06-02       Impact factor: 1.271

7.  Development and evaluation of an artificial intelligence system for COVID-19 diagnosis.

Authors:  Cheng Jin; Weixiang Chen; Yukun Cao; Zhanwei Xu; Zimeng Tan; Xin Zhang; Lei Deng; Chuansheng Zheng; Jie Zhou; Heshui Shi; Jianjiang Feng
Journal:  Nat Commun       Date:  2020-10-09       Impact factor: 14.919

Review 8.  The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD.

Authors:  Martin Kolb; Stylianos E Orfanos; Chris Lambers; Kevin Flaherty; Alison Masters; Lisa Lancaster; Adam Silverstein; Steven D Nathan
Journal:  Adv Ther       Date:  2022-07-03       Impact factor: 4.070

Review 9.  Exercise-Based Pulmonary Rehabilitation for Interstitial Lung Diseases: A Review of Components, Prescription, Efficacy, and Safety.

Authors:  Renata G Mendes; Viviane Castello-Simões; Renata Trimer; Adriana S Garcia-Araújo; Andrea Lucia Gonçalves Da Silva; Snehil Dixit; Valéria Amorim Pires Di Lorenzo; Bruno Archiza; Audrey Borghi-Silva
Journal:  Front Rehabil Sci       Date:  2021-11-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.